The present study aimed to compare cancer incidence and trends in survival for children diagnosed in Japan and England, using population-based cancer registry data.
The incidence of childhood cancer overall and by diagnostic subgroup has been reported in the International Incidence of Childhood Cancer (IICC) for many countries, including Japan and England. 2, 3 In Europe, survival analysis has been performed to evaluate the quality of care for children with cancer in each country or region in several studies, including the Automated Childhood Cancer Information System (ACCIS) 4 and EUROCARE-5. 5 In 2012, the global surveillance of cancer survival program (the CONCORD-2 study), 6, 7 which includes childhood leukemia, was initiated using population-based cancer registry data from 67 countries. In Japan, population-based studies for childhood cancer comparisons to other countries are scarce, although some recent studies show childhood cancer incidence 8, 9 or survival, 10 and several cancer registries contributed to the IICC and CONCORD-2 studies. 2, 7 In England, population-based incidence and survival for childhood cancer have been reported since 1980s. [11] [12] [13] In the current study, we compared incidence and time trends in survival for childhood cancer between Japan and England during the period 1993-2010, to gain insight into the progress against childhood cancer in both countries.
| ME TH ODS

| Data
This study was based on data from population-based cancer registries in Japan and England. It included all children (0-14 years) diagnosed with cancer between 1993 and 2010 residing in 6 Japanese prefectures (Miyagi, Yamagata, Niigata, Fukui, Osaka and Nagasaki) 10 or in England. Japanese data were obtained from the Monitoring of Cancer Incidence in Japan (MCIJ) project and the Japanese Cancer Survival Information for Society (J-CANSIS) project, 10 while data for England were obtained from the Office for National Statistics. A standard set of variables included basic demographic data (age, sex and country), information on the tumor (date of diagnosis, site and morphology) and on follow-up (date of last contact and vital status). Follow-up information was available at least 5 years after diagnosis in Japan although the patient follow-up system differs for each cancer registry. 10 Within the Japanese data, vital status information was available for patients diagnosed during 1993-2008. In the English data, the vital status was last updated on 31 December 2015.
We included only records of malignant cancers (behavior code/3) defined in the International Classification of Disease for Oncology, 3rd edition (ICD-O-3). 14 Non-malignant or borderline central nervous system tumors such as craniopharyngioma, meningioma, ganglioglioma, benign teratoma and pilocytic astrocytoma were all excluded. Skin carcinomas were also excluded. Cancers were grouped into 12 main diagnostic categories according to the International Classification of Childhood Cancer, 3rd edition (ICCC-3). 15 We modified some subgroups of ICCC-3, based on the topography and morphology codes from ICD-O-3 (Table S1 ).
These data partially overlapped with the data used in the IICC or CONCORD-2, although for participating registries or study periods, inclusion criteria were not completely matched. There were few discrepancies in the incidence of each cancer between both datasets, with the exception of central nervous system (CNS) tumors and all cancers combined.
| Statistical analysis
Incidence rates were calculated as the average annual number of children newly diagnosed with cancer per million children. Agestandardized incidence rates (ASR) were calculated by the direct method, using the weights of the world standard population for the age groups under 15 years (0, 1-4, 5-9 and 10-14 years). 16, 17 Changes in incidence rates over time were calculated using a Poisson regression model, divided into 3 time periods (1993-1998, 1999-2004 and 2005-2010) and adjusted for age-group, and expressed as average annual percent change (AAPC). Differences in incidence rates between the 2 countries were measured with Poisson regression models and expressed as the incidence rate ratio (IRR), using English data as the reference. These ratios were adjusted for time period and age group. Observed population-based survival was estimated by cancer type in each time period (1993-1996, 1997-2000, 2001-2004 and 2005-2008) , using the Kaplan-Meier method. We used the classic cohort approach to calculate 1- 
| RESULTS
| Data quality
Analyses were based on 5192 cases in Japan and 21 295 cases in England between 1993 and 2010. Table 1 shows the quality criteria for validity and completeness of the data over time in each country.
The proportion of records from death certificate only (DCO) in Japan reduced from 3.1% in 1993-1998 to 0.9% in 2005-2010, whereas that in England has been stable at under 1% since 1993.
The proportion of unspecified histology (not otherwise specified
[NOS], ICD-O-3 morphology code 8000 to 8004) also decreased from 4.3 to 2.1% in Japan, whereas that in England was around 2% from 1993 to 2010. 19 The proportion of multiple primary cancers was under 1% in both countries, except in the Japanese data for 2005-2010. We included NOS for both incidence and survival analysis while DCO and multiple primary cancers were excluded in survival analysis. NAKATA ET AL. | 423
| Trends in incidence of childhood cancer in
Japan and England Table 2 shows trends in incidence for each cancer type in both countries. Overall, the age-standardized incidence rate (ASR) of all childhood cancers combined seemed to decrease in Japan (ASR 1993-1998: 127 per million vs 2005-2010: 116 per million; see Table 2 and Figure S1A ). However, incidence for all cancers except neuroblastoma was stable (AAPC = 0.2%, [95% CI À0.4-0.8], Figure S1B ). In England, the incidence of all childhood cancers increased from 1993- Table 3 and Figure 1 show ASR in the total period of 1993-2010 and the incidence rate ratios (IRR) for each cancer type between Japan and England (England reference), adjusted for time period and age group. We analyzed age-specific incidence rates by sex for some solid tumors (Wilms tumor, hepatoblastoma and GCT of each site) in each country (Table S2 and Figure S2 ). The peak age for Wilms tumor in Japan was infants aged under 1 year, whereas in England it was children aged 1-4 years. Hepatoblastoma was the most common type of hepatic tumor in both countries (N = 100 [88%] in Japan vs N = 211 [82%] in England) and the age distribution was similar between countries. Age-specific incidence rates for intracranial GCT were higher in Japan than in England for all age groups. Incidence of gonadal GCT in male infants in Japan was much higher than in England. However, the numbers were too small to perform any relevant statistical comparison.
| Comparison of incidence of each cancer type between countries
| Trends in survival for each cancer type in
Japan and England
We analyzed trends in 1-year, 5-year and 10-year survival for each cancer type and each period in both countries ( To calculate 10-year survival in recent periods, we used a different approach (period approach) from the cohort approach, so there was divergence between 5-year survival and 10-year survival (higher survival in 10-year survival than 5-year survival) in some cancers (lymphomas, NBL, renal tumors, and unspecified cancers in Japan, and AML, CML, NBL infants, and GCT in England). Figure 2 
| DISCUSSION
In this study, we compared incidence and trends in survival for each childhood cancer type in Japan and England. Incidence of all childhood cancers combined decreased in Japan throughout 1993-2010 ( Figure S1A ), whereas in England incidence for all cancers combined was stable from 1999-2004 to 2005-2010, after a slight increase in the earlier period. However, analysis of the incidence by cancer type showed that the trends in cancer-specific incidence hardly varied in each county, except for neuroblastoma in Japan ( Table 2 ). The apparent drop in incidence for neuroblastoma in Japan was probably due to the cessation of the national screening program for neuroblastoma, which had been conducted as urine tests for all infants at 6 months of age since 1985. 20, 21 The Ministry of Health, Labour and Welfare terminated the program in 2004 on the basis of the self-healing potential of infant NBL and the negative effects of screening on mortality. 22 In the most recent period, after the cessation of this screening program in Japan, incidence for all cancers was higher in England than in Japan (ASR 2005-2010 139 vs 116). The incidence of many cancer types differed between Japan and England.
In England, incidence of HL, renal tumors and Ewing sarcomas was more than double that of Japan. Previous studies have shown racial T A B L E 2 (Continued) AAPC, average annual percentage of change; ASR, age-standardized incidence rate (person per million-years); CNS, central nervous system; NBL, neuroblastoma; n.a., AAPCs of "NBL infants (age < 1 y)"
were not calculated because models were not fitted. a Age-specific incidence rate. b Using records, population and world standard population in age 1-4, 5-9, 10-14 y. differences in incidence for these cancers. [23] [24] [25] [26] [27] [28] [29] Etiological factors of HL have been suggested by the bimodal age distribution, by elevated risks in males, by the occurrence of Epstein-Barr virus in HL tumor cells, and by identifying inherited susceptibility genes; however, the mechanism by which racial differences in incidence for HL occur is still unclear. Regarding renal tumors, previous studies which reported on differences in age distribution between countries for Wilms tumor showed the peak age for occurrence in East Asia to be infants (age <1 year), but among Caucasians in the USA the peak occurrence was older. 24, 25 Our study supports these findings (Table S2 and Wilms tumor between Japanese and Caucasians. 26, 27 For Ewing sarcomas, one report showed that Japanese Ewing sarcoma patients have a higher frequency of loss of chromosome 19 than European Caucasian patients. 28 However, these tumors are rare and their etiology has not been sufficiently investigated to explain these differences in incidence. 29 Regarding the higher incidence of AML in Japan, Bessho reported the mis-classification of ALL to ANLL (AML), T A B L E 3 Age-standardized incidence rate (ASR) and incidence rate ratio (IRR, England reference) of childhood cancer (age 0-14 y) in Japan and England, 1993-2010 which overestimated the proportion of ANLL in the 1970s. 30 However, nowadays, diagnosis of leukemia has become much more accurate and the proportion of unknown leukemia subtype was only approximately 5% in our data ( Table 3 ). The ALL:AML ratio in our data was 2.4:1, which is similar to that found in the report of the Japanese pediatric leukemia study group (JPLSG), containing information on molecular abnormalities collected by pediatric oncologists (ALL: AML = 2.8:1). 31 On the IICC-3 website, the ASR of AML was around 10 per million person-years in Japan and Korea, 32 whereas the figure was around 7 per million person-years in an Austria-based study. 19 The CONCORD-2 study on cancer survival reported higher proportions of AML in Asia than in Europe. 7 In the US data, there are no large racial differences in incidence for AML. 33 Further research will be needed to clarify whether the differences we have observed are due to underlying ethnic difference in the incidence of AML.
When comparing incidence for each subgroup, the proportion of "unspecified" histology within each cancer group should be taken into account (Table 3 ). The proportion of "unspecified" lymphomas (ICCC-3 II-e; 18%) or "unspecified" CNS tumors (ICCC-3 III-f; 16%)
in Japan was over 10% within each cancer group in the total period (1993-2010), although it decreased to under 10% in the most recent periods (data not shown).
Five-year survival for most cancer types improved in both Japan and England. (Table 4) 
| Cancer strategy for childhood cancer
Since 1974, the Japanese Government has subsidized medical expenses for children and adolescents under 18 years of age with cancer. 40 The There are 20 specialized hospitals for childhood cancer, known as principal treatment centers, and over 80 shared care centers, known as Paediatric Oncology Shared Care Units. In Europe, similar but less detailed standards of care for children with cancer were published in 2013, 41 with an international survey of the extent of their implementation published in 2016. 42 All standards recommend coordinated patient care and international collaboration in research. In this study, we looked at the trends in cancer incidence and survival in children over a 15-year period for Japan and England, by using population-based cancer registry data and compared them during the same periods for each cancer type. One limitation of our study is the small number of records available in the Japanese dataset. Prefectural cancer registry data were only available for 6 prefectures, representing 14% of the total population, 10 because other registries did not have such long-term data with patients' vital status information. In 2013, a law for cancer registration was established in Japan and a nationwide cancer registration system started in 2016.
Another limitation was the divergence between 5-year survival and 10-year survival (higher survival in 10-year survival than 5-year survival) in several cancers because we used the period approach to predict 10-year survival in recent periods. To improve surveillance and comparability, we need to keep collecting data widely and precisely, and follow up patients' vital status in the long term.
In conclusion, the incidence rates of the majority of childhood cancers differed significantly between Japan and England. Some of 
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F I G U R E 2 Five-year survival for each cancer type in Japan and England, 1993 England, -1996 England, and 2005 England, -2008 Five-year survival for some major diagnostic groups in Japan and England are plotted on the same graphic for each period. ALL, acute lymphoblastic leukemias; AML, acute myeloid leukemias; CML, chronic myeloid leukemia; CNS, central nervous system; NBL, neuroblastoma; RMS, rhabdomyosarcoma
